IL155100A0 - Pharmaceutical compositions comprising 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulphonyl]-urea as active ingredient - Google Patents

Pharmaceutical compositions comprising 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulphonyl]-urea as active ingredient

Info

Publication number
IL155100A0
IL155100A0 IL15510003A IL15510003A IL155100A0 IL 155100 A0 IL155100 A0 IL 155100A0 IL 15510003 A IL15510003 A IL 15510003A IL 15510003 A IL15510003 A IL 15510003A IL 155100 A0 IL155100 A0 IL 155100A0
Authority
IL
Israel
Prior art keywords
toluidino
sulphonyl
pyridyl
urea
isopropyl
Prior art date
Application number
IL15510003A
Other languages
English (en)
Original Assignee
Cosma S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosma S P A filed Critical Cosma S P A
Publication of IL155100A0 publication Critical patent/IL155100A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL15510003A 2002-03-27 2003-03-26 Pharmaceutical compositions comprising 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulphonyl]-urea as active ingredient IL155100A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI000639A ITMI20020639A1 (it) 2002-03-27 2002-03-27 Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea

Publications (1)

Publication Number Publication Date
IL155100A0 true IL155100A0 (en) 2003-10-31

Family

ID=11449588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15510003A IL155100A0 (en) 2002-03-27 2003-03-26 Pharmaceutical compositions comprising 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulphonyl]-urea as active ingredient

Country Status (5)

Country Link
US (2) US7034159B2 (xx)
EP (1) EP1348435A1 (xx)
CA (1) CA2423550A1 (xx)
IL (1) IL155100A0 (xx)
IT (1) ITMI20020639A1 (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
JP2003527319A (ja) * 1999-08-11 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド トルセミド多形体
DE60103276T2 (de) * 2000-02-17 2005-06-23 Teva Pharmaceutical Industries Ltd. Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält

Also Published As

Publication number Publication date
US7034159B2 (en) 2006-04-25
ITMI20020639A0 (it) 2002-03-27
US20030187032A1 (en) 2003-10-02
US20070054944A1 (en) 2007-03-08
ITMI20020639A1 (it) 2003-09-29
EP1348435A1 (en) 2003-10-01
CA2423550A1 (en) 2003-09-27

Similar Documents

Publication Publication Date Title
HUP0501186A2 (en) Pharmaceutical compositions comprising active vitamin d compounds
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL163846A0 (en) Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1631239A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE COMPOUNDS OF VITAMIN D
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
IL164519A0 (en) Pharmaceutical formulations
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
HK1087399A1 (en) Pharmaceutical formulations comprising highly purebases of 3, 3-giphenylpropylamine monoesters
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
GB2392093B (en) Pharmaceutical formulations
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
AU2002340573A8 (en) Powdery active ingredient formulations
HUP0203226A3 (en) Pharmaceutical composition comprising benzamide derivative as active ingredient
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them
IL155100A0 (en) Pharmaceutical compositions comprising 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulphonyl]-urea as active ingredient
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
HRP20040757A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii
AU2003238900A8 (en) Pharmaceutical formulation